Evidence map›Paper›PMID 40996645›Full record

ArticleBulletin of experimental biology and medicine2025

Antiparkinsonian Activity of Benzenesulfonamide Derivatives, Selective MAO-B Inhibitors.

A L Khokhlov, V N Fedorov, A A Shetnev, M K Korsakov, S S Petukhov, V P Vdovichenko, A A Khokhlova, S Sh Suleimanov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A L KhokhlovYaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russia.
V N FedorovYaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russia.
A A ShetnevM. V. Dorogov Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University Named after K. D. Ushinsky, Yaroslavl, Russia.
M K KorsakovM. V. Dorogov Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University Named after K. D. Ushinsky, Yaroslavl, Russia. mkkors@mail.ru.
S S PetukhovM. V. Dorogov Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University Named after K. D. Ushinsky, Yaroslavl, Russia.
V P VdovichenkoYaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russia.
A A KhokhlovaYaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russia.
S Sh SuleimanovYaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-parkinsonian activity of benzolsulfonamide selective MAO-B inhibitors was evaluated in a model of experimental parkinsonism in white mice (systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPTP). Six candidate compounds (laboratory codes S6-S8 and S11-S13) were analyzed. Rasagiline was used as the reference drug. Only compound S13 was comparable to rasagiline in preventing the development of rigidity and hypokinesia in animals and surpassed the reference drug in correcting emotional and behavioral activity.

Indexed as

Antiparkinson AgentsMonoamine Oxidase InhibitorsSulfonamides1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsDisease Models, AnimalIndansMaleMiceMonoamine Oxidase1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAntiparkinson AgentsIndansMonoamine OxidaseMonoamine Oxidase InhibitorsrasagilineSulfonamidesbenzenesulfonamide derivativeexperimental parkinsonismMAO inhibitorsParkinson’s disease

Identifiers

PMID40996645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.